[REPRESENTATION OF LOGO]
NICO WATER (TM)

                                                                    Exhibit 99.2


        QT 5, INC. PROVIDES REVENUE AND EARNINGS GUIDANCE FOR FISCAL 2004

                              ---------------------

                  FORECASTS REVENUES OF $27.2 MILLION, EPS OF
                     $0.08 FOR FISCAL YEAR COMMENCING JULY 1


Westlake Village, CA (PR Newswire) June 2, 2003 - QT 5, Inc. (OTC BB: QTFV)
manufacturer and marketers of NICOWater(TM), the breakthrough Homeopathic
nicotinum (nicotine) product designed to relieve the symptoms of tobacco
cravings, today announced that it anticipates Revenues of $27.2 million for
fiscal 2004 commencing July 1, 2003. The Company also announced that it
anticipates Net Income for the same fiscal period of $3.5 million, resulting in
$0.08 Earnings Per Share, based on fully diluted shares outstanding. The
announcement was made by Steven Reder, QT 5, Inc.'s President. On May 28, 2003,
the Company announced the official national launch and rollout of NICOWater(TM).

"In four weeks we commence our new fiscal year - a year in which we will now
begin to capitalize on the earnings and revenue power of NICOWater(TM), stated
Steven Reder, QT 5's President. "We now fully expect QT 5's growth to be
extraordinary this coming fiscal year as we demonstrate the commercial viability
of this revolutionary product. Our seasoned management team is committed to
increasing shareholder value through well-planned earnings and revenue growth,
with NICOWater(TM) serving as a core driver. Our corporate mantra is growth,
earnings and increasing shareholder value. QT 5, Inc. has targeted the massive
$200 billion tobacco and tobacco products market -- which we believe offers
exceptional opportunity for such timely product."


CONFERENCE CALL AND WEBCAST

Within the context of QT 5, Inc. management's commitment to maximum
transparency, the Company will be hosting a webcast and conference call on
Monday, June 2, 2003 at 11 am Eastern to discuss the successful launch and
rollout of NICOWater(TM), as well as the Company's Revenues and Earnings
Guidance for the coming fiscal year. Steven Reder, President of QT 5, Inc., and
other members of the executive management team will be available to answer
questions and discuss the current state of the Company. Investors may e-mail
questions in advance of the call to A.J. Cervantes, President of Trilogy Capital
Partners, at aj@trilogy-capital.com. Participants in the conference can call
800.406.5356 domestically, or by calling 913.981.5572 from an international
location. Investors should indicate they are participating in the "QT 5 Guidance
Call." To access the webcast, investors who would like to pre-register for the
webcast can log on to www.qt5inc.com



The webcast will also be distributed over the Shareholder.com Investor
Distribution Network to both institutional and individual investors including
OpenCompany.info, a corporate disclosure network providing information on over
6,000 public companies to the investment community and to participating portals
and websites.

ABOUT QT 5


QT 5, Inc. is a Delaware corporation formed in April 1999 as a manufacturer,
distributor and marketer of Bio-Med testing and Homeopathic products. QT 5, Inc.
is continuing its clinical research and development of future products for
lifestyle enhancements. QT 5, Inc. is headquartered in Westlake Village,
California. For more information please visit: www.qt5inc.com. NICOWater(TM) is
a Homeopathic Drug product that is sold under the FDA's Compliance Policy Guide
Conditions under which Homeopathic Drugs may be Marketed. For additional
information on QT 5, Inc. contact Bernadette Cusack, Vice President - Investor
Relations, Trilogy Capital Partners, bernadette@trilogy-capital.com.

                         ------------------------------



CAUTIONARY STATEMENT

This release contains forward-looking statements that involve risks and
uncertainties, such as statements about our plans, objectives, expectations,
assumptions or future events. These statements involve estimates, assumptions,
known and unknown risks, uncertainties and performances, or achievements
expressed or implied by the forward-looking statement. Actual future results and
trends may differ materially from those made in or suggested by any
forward-looking statements due to a variety of factors, including, for example,
our ability to compete with other products in our space; the risk of unfavorable
federal regulation; and the fact that our status as a development sate company
makes our future unclear. Consequently you should not place undue reliance on
these forward-looking statements. We discuss many of these and other risks and
uncertainties in greater detail under the section entitled, "Risk Factors That
May Affect Future Results" in Item 1 of the Company's Current Report on Form 8-K
as filed with SEC on January 24, 2003 (the "Merger Form 8-K").

CONTACT

Bernadette Cusack, Vice President
Trilogy Capital Partners, Inc.
800.330.6540
aj@trilogy-capital.com